Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXA2R | P21731 | 7/20 | 0.53 |
| ▸ | MME | P08473 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | CPT2 | P23786 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL446707 | 0.85 | TBXA2R (0.44) | TBXA2RMMEMEN1KMT2ALMNA | |
| SCHEMBL6809133 | 0.83 | BLM (0.58) | TBXA2RMEN1KMT2ACYP2C19HIF1A | |
| SCHEMBL473504 | 0.82 | CYP2C19 (0.53) | TBXA2RLMNACYP2C19HIF1AKDM4E | |
| SCHEMBL447459 | 0.82 | CYP2C19 (0.50) | TBXA2RMMEMEN1KMT2ALMNA | |
| SCHEMBL8834986 | 0.82 | FFAR1 (0.43) | TBXA2RMMEMEN1KMT2ALMNA | |
| SCHEMBL8834980 | 0.82 | SLC13A5 (0.49) | TBXA2RMMEFFAR1CPT2TDP1 | |
| SCHEMBL17590423 | 0.81 | TBXA2R (0.54) | TBXA2RLMNACYP2C19 | |
| SCHEMBL29922059 | 0.80 | RIPK1 (0.47) | TBXA2RFFAR1 | |
| SCHEMBL11827472 | 0.80 | TBXA2R (0.44) | TBXA2RMMEMEN1KMT2ALMNA | |
| SCHEMBL30338274 | 0.80 | TAAR1 (0.43) | LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065195-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | ARRAY BIOPHARMA INC. | 2012-03-15 | — | — | US | disclosed |
| WO-2011123674-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | ARRAY BIOPHARMA INC. (US) | 2011-10-06 | — | — | WO | disclosed |
| US-4800212-A | Pyrrolidone-2 compounds and anti-hypertensive use thereof | BEECHAM GROUP P.L.C. (GB) | 1989-01-24 | — | — | US | disclosed |
| EP-0168619-B1 | N-ACYLATED DI- OR TETRAHYDRONAPHTHALENAMINES, AND ANTIHYPERTENSIVE COMPOSITIONS CONTAINING THEM | BEECHAM GROUP PLC (GB) | 1988-08-24 | — | — | EP | disclosed |
| EP-0168619-A1 | N-acylated di- or tetrahydronaphthalenamines, and antihypertensive compositions containing them | BEECHAM GROUP PLC (GB) | 1986-01-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065195-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | APP, BACE1, PSEN1 | TBXA2R 3092/4885MME 50/4885MEN1 1819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.